Integrum AB (publ), the medical technology company that improves the lives of amputees, cordially invites you to an online investor information session on September 25, 2024, @ 3 pm CEST.
This session will feature our acting CEO Scott Flora, and CFO, Jörgen Svanström, who will share insights into the company’s strategic direction and upcoming initiatives. A warm welcome to join us to learn more about Integrum’s next steps.
When: 25 September 2024 @3pm-3.30pm
Where: https://www.finwire.tv/webcast/integrum/integrum-meeting/
We look forward to seeing you online!
For more information, please contact Scott Flora, CEO, by email scott.flora@integrum.se
Certified Adviser
Carnegie Investment Bank AB (publ) is Certified Adviser.
About Integrum
Integrum is a publicly traded company (Nasdaq First North Growth Market: INTEG B) based outside of Gothenburg, Sweden, with a U.S. subsidiary in San Francisco. Since 1990, its OPRA® Implant System has helped improve the quality of life for hundreds of people who are amputees by directly attaching a prosthesis to the bone and musculoskeletal system, therefore avoiding the need for a socket. Based on osseointegration, the bone-anchored implant system offers a range of benefits, including improved mobility and function, enhanced comfort, reduced pressure, a stable attachment and more. The OPRA® Implant System was approved by the U.S. Food and Drug Administration (FDA) in 2020 and is the only FDA-approved bone-anchored implant system specifically designed for use in amputees available in the U.S. Today, Integrum continues to perform research and develop custom-made medical device solutions in close collaboration with scientists and clinicians. To learn more, please visit https://integrum.se/.